Vitamin D HIV Study

This study is currently recruiting participants. (see Contacts and Locations)
Verified August 2014 by Columbia University
Sponsor:
Collaborator:
Information provided by (Responsible Party):
Elizabeth Shane, Columbia University
ClinicalTrials.gov Identifier:
NCT01375010
First received: June 15, 2011
Last updated: August 20, 2014
Last verified: August 2014
  Purpose

The purpose of this study is to determine the effects of vitamin D on measures of bone health and immune function in HIV infected postmenopausal women. The investigators prior research with this population revealed that low vitamin D levels are very common. Prior research with this population also revealed that Vitamin D is necessary for the body to absorb calcium and is important for the health of the bones. When vitamin D levels are low, there are increased risks of bone loss, muscle weakness, falls and fractures. Low levels of vitamin D have also been associated with impaired immune function. This study will help us learn whether two different doses of vitamin D will improve bone health and immune function.


Condition Intervention Phase
HIV
Drug: Vitamin D3
Drug: Placebo
Phase 1
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: The Effect of Vitamin D Repletion on Postmenopausal Women With HIV

Resource links provided by NLM:


Further study details as provided by Columbia University:

Primary Outcome Measures:
  • Change in Bone Mineral Density (BMD) [ Time Frame: 12 months ] [ Designated as safety issue: No ]
    Percent change from baseline in BMD at lumbar spine (as measured by Dual-emission X-ray absorptiometry (DXA) scan) at 12 months


Secondary Outcome Measures:
  • Areal Change in Bone Mineral Density (aBMD) [ Time Frame: 12 months ] [ Designated as safety issue: No ]
    To evaluate the change in areal BMD (aBMD) at the total hip (TH), femoral neck (FN), and distal radius (DR);

  • Change in Volumetric Bone Mineral Density (vBMD) [ Time Frame: 12 months ] [ Designated as safety issue: No ]
    To evaluate the change in volumetric BMD (VBMD) at the radius, tibia, hips and lumbar spine

  • Change in Vitamin D levels [ Time Frame: 12 months ] [ Designated as safety issue: No ]
    To evaluate the change in vitamin D levels with supplementation

  • Change in Biochemical markers [ Time Frame: 12 months ] [ Designated as safety issue: No ]
    To evaluate the effect of vitamin D and calcium supplementation on biochemical markers of bone turnover and markers of inflammation.

  • Change in Immune function [ Time Frame: 12 months ] [ Designated as safety issue: No ]
    To evaluate the effect of vitamin D supplementation on biochemical markers of immune function

  • Change in Muscle measures and frailty [ Time Frame: 12 months ] [ Designated as safety issue: No ]
    To evaluate the effect of vitamin D supplementation on muscle strength.

  • Change in Biochemical Markers [ Time Frame: 12 months ] [ Designated as safety issue: No ]
    To evaluate the effect of vitamin D and calcium supplementation on biochemical markers of inflammation.

  • Change in Muscle measures and frailty [ Time Frame: 12 months ] [ Designated as safety issue: No ]
    To evaluate the effect of vitamin D supplementation on functional muscle performance.


Estimated Enrollment: 100
Study Start Date: January 2011
Estimated Study Completion Date: December 2015
Estimated Primary Completion Date: December 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Group A
1000 IU vitamin D + placebo capsule = 1000 IU/day of vitamin D
Drug: Vitamin D3
All subjects will be provided with supplements that contain 500 mg of calcium (carbonate) and 500 IU of vitamin D3 and will be instructed to take one twice daily with breakfast and dinner. Participants will then be block randomized in a 1:1 ratio with randomly varying block sizes of 2, 4 or 6 to 2000 IU vitamin D3 (Group A) or placebo (Group B). Group A will receive a total of 3000 IU/day, the dose and Group B will receive 1000 IU/day.
Drug: Placebo
Participants will then be block randomized in a 1:1 ratio with randomly varying block sizes of 2, 4 or 6 to 2000 IU vitamin D3 (Group A) or placebo (Group B). Group A will receive a total of 3000 IU/day, the dose and Group B will receive 1000 IU/day.
Experimental: Group B
1000 IU vitamin D + 2000 IU vitamin D = 3000 IU/day of vitamin D
Drug: Vitamin D3
All subjects will be provided with supplements that contain 500 mg of calcium (carbonate) and 500 IU of vitamin D3 and will be instructed to take one twice daily with breakfast and dinner. Participants will then be block randomized in a 1:1 ratio with randomly varying block sizes of 2, 4 or 6 to 2000 IU vitamin D3 (Group A) or placebo (Group B). Group A will receive a total of 3000 IU/day, the dose and Group B will receive 1000 IU/day.

Detailed Description:

The purpose of this study is to determine the effects of vitamin D repletion on rates of bone loss and indices of immune function in HIV+ postmenopausal women. Lower baseline serum Vitamin D levels, as assessed by measuring serum 25-hydroxyvitamin D (25-OHD) were associated with a trend toward more bone loss. In addition, the investigators found that despite providing supplements that contained approximately 600 IU vitamin D, serum 25-OHD did not increase during the first year. Provision of adequate calcium and vitamin D is the cornerstone of effective prevention and therapy of osteoporosis. HIV-infected patients may be at increased risk of having vitamin D deficiency because they take several medications that may interfere with vitamin D action. Therefore, the investigators will recruit 100 HIV infected postmenopausal women for this study who are on a stable antiretroviral therapy (ART) regimen and randomize them to receive 1000 or 3000 IU of vitamin D daily. The subjects will be followed closely for one year to monitor compliance and changes in bone health and immune function.

  Eligibility

Ages Eligible for Study:   40 Years to 70 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • HIV+ African American and Latina postmenopausal women, aged 40-70, who meet the standard definition of menopause:

If 50 years old or older then amenorrhea for > 1year. If age 40 to 49 then amenorrhea for over a year and and Follicle-Stimulating Hormone (FSH) level of equal to or greater than 20 mIU/ml; as some amenorrheic chronically ill women may have hypothalamic dysfunction and low FSH values, if FSH is 10 to 19, and the serum estradiol level is consistent with menopause less than or equal to 30pg/ml, she will be determined to be postmenopausal.

  • On stable antiretroviral therapy (ART) for >2 years
  • Undetectable HIV RNA (viral load) at least 2 times over the past year (RNA <400)

Exclusion Criteria:

  • Metabolic bone disease (Paget's disease, clinical osteomalacia, primary hyperparathyroidism, hypercalcemia)
  • Multiple myeloma, solid tumors with metastases;
  • Endocrinopathy (hyperthyroidism, untreated hypothyroidism, Cushing's syndrome, prolactin-secreting pituitary adenoma)
  • Renal insufficiency (serum creatinine above 1.5 mg/dl)
  • Liver disease (AST, ALT, bilirubin, total alkaline phosphatase activity > twice upper normal limit);
  • Intestinal disorders (celiac disease, pancreatic insufficiency, Crohn's disease, ulcerative colitis)
  • Current use of glucocorticoids, anticonvulsants, anticoagulants, diuretics, methotrexate;
  • Current or past use of drug therapies for osteoporosis (raloxifene, bisphosphonates, calcitonin, PTH). Women on estrogen are excluded. Past estrogen use is permitted if discontinued >1 year before enrollment.
  • If there is a history of a low trauma fracture, a T score < -3 or a prevalent vertebral fracture on Instant Vertebral Assessment™ (IVA), subjects will be referred for osteoporosis treatment as appropriate.
  • Severe vitamin D deficiency (25-OHD level <10 ng/ml) or normal baseline serum vitamin D (25-OHD >32 ng/ml). Subjects with severe vitamin D deficiency may be referred to our sub-study, if all other inclusion/exclusion criteria are met.
  • Hypercalcemia or history of calcium-containing kidney stones
  • Known allergy/sensitivity or any hypersensitivity to components of study drugs or their formulations
  • Current imprisonment or voluntary incarceration in a medical facility for psychiatric illness
  • Any condition that, in the opinion of the site investigator, would compromised the subject's ability to participate in the study
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01375010

Contacts
Contact: Michael Yin, MD mty4@columbia.edu
Contact: Mariana Bucovsky 2123057225 mb3523@columbia.edu

Locations
United States, New York
Columbia University Medical Center Recruiting
New York, New York, United States, 10032
Contact: Michael Yin, MD       mty4@columbia.edu   
Sponsors and Collaborators
Columbia University
Investigators
Principal Investigator: Elizabeth Shane, MD Columbia University
Study Director: Michael Yin, MD Columbia University
  More Information

No publications provided

Responsible Party: Elizabeth Shane, Professor of Medicine, Endocrinology, Columbia University
ClinicalTrials.gov Identifier: NCT01375010     History of Changes
Other Study ID Numbers: AAAF2194, 2R01AI065200-06A1
Study First Received: June 15, 2011
Last Updated: August 20, 2014
Health Authority: United States: Institutional Review Board

Keywords provided by Columbia University:
HIV
Postmenopausal women
Vitamin D

Additional relevant MeSH terms:
Cholecalciferol
Ergocalciferols
Vitamin D
Vitamins
Bone Density Conservation Agents
Growth Substances
Micronutrients
Pharmacologic Actions
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on October 20, 2014